FDA’s Shuren On Why Agency Broke Up Its IVD And Radiological Health Office
Executive Summary
The US FDA split its Office of In Vitro Diagnostics and Radiological Health in two earlier this week because it “really had two flavors of technology – actually three – that sat in there,” says Jeff Shuren, director of the agency’s device center.
You may also be interested in...
FDA Expands OPEQ ‘Super Office’; Splits In Vitro Diagnostics, Radiological Health Office In Two
The US agency’s Office of Product Evaluation and Quality also created new divisions in its Office of Regulatory Programs and Office of Clinical Evidence and Analysis.
Speaking Of Medtech, Ep. 10: FDA’s TAP Pilot
In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?
Thumbs Up: FDA Authorizes Weight Loss Suturing Systems From Apollo Endosurgery
People with obesity now have new tools to help them lose weight, thanks to the US agency’s de novo authorization.